Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Cigna Group stock logo
CI
The Cigna Group
$315.25
-0.2%
$325.14
$262.03
$370.83
$84.41B0.471.71 million shs1.48 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$550.19
+2.0%
$513.67
$396.15
$616.00
$197.20B1.71.64 million shs1.24 million shs
Medtronic plc stock logo
MDT
Medtronic
$81.14
+0.6%
$84.64
$75.96
$96.25
$104.07B0.816.79 million shs8.29 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$446.00
+2.3%
$473.44
$377.85
$519.88
$114.53B0.511.41 million shs2.05 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Cigna Group stock logo
CI
The Cigna Group
-0.35%-2.93%-6.06%+3.31%-5.22%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+1.97%-1.25%+6.92%-5.29%+35.90%
Medtronic plc stock logo
MDT
Medtronic
+0.54%-5.86%-3.62%-10.42%-1.40%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+2.29%-0.26%-9.69%-6.91%-2.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Cigna Group stock logo
CI
The Cigna Group
4.9641 of 5 stars
3.53.03.34.24.12.52.5
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.2163 of 5 stars
2.43.00.04.03.62.51.9
Medtronic plc stock logo
MDT
Medtronic
4.8496 of 5 stars
3.24.03.34.03.21.71.9
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4.6489 of 5 stars
3.35.00.03.34.22.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Cigna Group stock logo
CI
The Cigna Group
3.00
Buy$379.3320.33% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.75
Moderate Buy$596.058.33% Upside
Medtronic plc stock logo
MDT
Medtronic
2.47
Hold$96.0718.40% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.57
Moderate Buy$515.0415.48% Upside

Current Analyst Ratings Breakdown

Latest MDT, VRTX, ISRG, and CI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
The Cigna Group stock logo
CI
The Cigna Group
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$388.00
5/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$590.00 ➝ $650.00
5/22/2025
Medtronic plc stock logo
MDT
Medtronic
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$100.00 ➝ $98.00
5/22/2025
Medtronic plc stock logo
MDT
Medtronic
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$105.00 ➝ $101.00
5/22/2025
Medtronic plc stock logo
MDT
Medtronic
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$94.00 ➝ $92.00
5/19/2025
Medtronic plc stock logo
MDT
Medtronic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/12/2025
The Cigna Group stock logo
CI
The Cigna Group
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$385.00 ➝ $405.00
5/7/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/6/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Cigna Group stock logo
CI
The Cigna Group
$254.47B0.33$39.75 per share7.93$148.27 per share2.13
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.71B22.63$7.25 per share75.93$46.41 per share11.85
Medtronic plc stock logo
MDT
Medtronic
$33.54B3.10$6.65 per share12.21$38.69 per share2.10
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.10B10.32N/AN/A$63.90 per share6.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Cigna Group stock logo
CI
The Cigna Group
$3.43B$18.0625.769.540.981.39%18.61%4.98%8/7/2025 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$6.8285.8372.115.8527.81%14.55%12.88%7/17/2025 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.6224.6613.922.2212.83%14.07%7.70%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$3.92N/A25.472.11-4.86%-2.02%-1.49%8/7/2025 (Estimated)

Latest MDT, VRTX, ISRG, and CI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2025
Medtronic plc stock logo
MDT
Medtronic
$1.58$1.62+$0.04$0.82$8.81 billion$8.93 billion
5/5/2025Q1 2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion
5/2/2025Q1 2025
The Cigna Group stock logo
CI
The Cigna Group
$6.35$6.74+$0.39$4.85$60.39 billion$65.45 billion
4/22/2025Q1 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.71$1.81+$0.10$1.92$2.19 billion$2.25 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Cigna Group stock logo
CI
The Cigna Group
$6.041.92%+11.87%33.44%5 Years
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.843.50%+4.14%78.45%49 Years
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest MDT, VRTX, ISRG, and CI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/21/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.713.3%6/27/20256/27/20257/11/2025
4/23/2025
The Cigna Group stock logo
CI
The Cigna Group
quarterly$1.511.79%6/3/20256/3/20256/18/2025
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Cigna Group stock logo
CI
The Cigna Group
0.70
0.66
0.72
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.07
3.22
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.69
2.35

Institutional Ownership

CompanyInstitutional Ownership
The Cigna Group stock logo
CI
The Cigna Group
86.99%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
Medtronic plc stock logo
MDT
Medtronic
82.06%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
The Cigna Group stock logo
CI
The Cigna Group
0.70%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
Medtronic plc stock logo
MDT
Medtronic
0.20%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
The Cigna Group stock logo
CI
The Cigna Group
71,300267.14 million276.48 millionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
12,100358.42 million352.97 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4,800256.80 million256.28 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

The Cigna Group stock logo

The Cigna Group NYSE:CI

$315.25 -0.74 (-0.23%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$319.01 +3.76 (+1.19%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$550.19 +10.65 (+1.97%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$549.00 -1.19 (-0.22%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Medtronic stock logo

Medtronic NYSE:MDT

$81.14 +0.46 (+0.57%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$81.86 +0.72 (+0.89%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$446.00 +10.00 (+2.29%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$440.78 -5.22 (-1.17%)
As of 08:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.